UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
43.62
-1.88 (-4.13%)
At close: Aug 28, 2026, 4:00 PM EDT
44.98
+1.36 (3.12%)
After-hours: Aug 28, 2026, 7:59 PM EDT
UroGen Pharma Employees
UroGen Pharma had 300 employees as of June 30, 2026. The number of employees increased by 47 or 18.58% compared to the same quarter last year.
Employees
300
Change
47
Growth
18.58%
Revenue / Employee
$629,113
Profits / Employee
-$325,453
Market Cap
2.13B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 300 | 47 | 18.58% | 300 | 0 |
| Mar 31, 2026 | 298 | 64 | 27.35% | 298 | 0 |
| Dec 31, 2025 | 291 | 56 | 23.83% | 291 | 0 |
| Sep 30, 2025 | 287 | 70 | 32.26% | 287 | 0 |
| Jun 30, 2025 | 253 | 50 | 24.63% | 253 | 0 |
| Mar 31, 2025 | 234 | 30 | 14.71% | 234 | 0 |
| Dec 31, 2024 | 235 | 34 | 16.92% | 235 | 0 |
| Sep 30, 2024 | 217 | 25 | 13.02% | 217 | 0 |
| Jun 30, 2024 | 203 | 10 | 5.18% | 203 | 0 |
| Mar 31, 2024 | 204 | 10 | 5.15% | 204 | 0 |
| Dec 31, 2023 | 201 | 1 | 0.50% | 198 | 3 |
| Sep 30, 2023 | 192 | -3 | -1.54% | 192 | 0 |
| Jun 30, 2023 | 193 | -8 | -3.98% | 193 | 0 |
| Mar 31, 2023 | 194 | 2 | 1.04% | 194 | 0 |
| Dec 31, 2022 | 200 | 5 | 2.56% | 200 | 0 |
| Sep 30, 2022 | 195 | -3 | -1.52% | 195 | 0 |
| Jun 30, 2022 | 201 | 11 | 5.79% | 201 | 0 |
| Mar 31, 2022 | 192 | 2 | 1.05% | 192 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Maravai LifeSciences Holdings | 415 |
| Harmony Biosciences Holdings | 293 |
| Xencor | 260 |
| Zenas BioPharma | 167 |
| Aurinia Pharmaceuticals | 128 |
| Mesoblast | 108 |
| Nanobiotix | 100 |
URGN News
- 9 days ago - IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies - PRNewsWire
- 9 days ago - UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline - GlobeNewsWire
- 12 days ago - UroGen Pharma submits UGN-103 NDA to FDA - TheFly
- 12 days ago - UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC - GlobeNewsWire
- 23 days ago - UroGen Pharma price target raised to $60 from $50 at Oppenheimer - TheFly
- 23 days ago - UroGen Pharma price target raised to $58 from $42 at Guggenheim - TheFly
- 23 days ago - UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright - TheFly
- 24 days ago - UroGen Pharma price target raised to $60 from $50 at TD Cowen - TheFly